Inactive Instrument

MannKind Corporation Nasdaq

Equities

US56400P2011

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 26	MannKind CFO Binder to Retire in April, Names New CFO	MT
Mar. 26	MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	CI

MannKind Receives $30.6 Million From Sanofi

January 09, 2017 at 09:01 am EST

VALENCIA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. This payment was made pursuant to a previously disclosed agreement reached with Sanofi on November 9, 2016.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Rose Alinaya
SVP, Finance
661-775-5300
ralinaya@mannkindcorp.com

Primary Logo

Latest news about MannKind Corporation

MannKind CFO Binder to Retire in April, Names New CFO	Mar. 26	MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	Mar. 26	CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	Mar. 26	CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Transcript : MannKind Corporation - Special Call	Jan. 03
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million	Jan. 02	MT
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals	Dec. 28	MT
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	Dec. 18	MT
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	Nov. 14	MT
Transcript : MannKind Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M	Nov. 07	MT
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes	Nov. 06	CI
MannKind Receives US Patent for Clofazimine Inhalation Suspension to Treat Lung Disease	23-10-30	MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	23-10-10	MT
Transcript : MannKind Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 08:10 AM	23-09-13
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	23-08-14	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-08-08	MT
MannKind Reports Q2 Breakeven, Revenue Rises	23-08-08	MT

Chart MannKind Corporation

Duration

Period

More charts

Company Profile

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs